



May 12, 2021

Terumo Announces Dividends for Fiscal Year Ended March 31, 2021 (increased payment)

TOKYO, JAPAN – May 12, 2021 – Terumo Corporation (TSE: 4543) announced today it has approved the dividends for fiscal year ended March 31, 2021 at its Board of Directors meeting held on May 12, 2021. The year-end dividends for this fiscal year will increase as follows.

1. Details of Dividends

	Decided dividends	Latest dividends forecast (as of May 18, 2020)	FY2020 dividends (Actual)
Record date	March 31, 2021	March 31, 2021	March 31, 2020
Dividends per share	15.0JPY	14.0JPY	14.0JPY
Total amount of dividends	11,340 million JPY	-	10,531 million JPY
Dividends payment starting date	June 23, 2021	-	June 26, 2020
Source of dividends	Retained earnings	-	Retained earnings

2. Reason

As a measure to secure high profit margins and sustainable growth, Terumo is committed to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo will continually aim to steadily increase its dividend payouts to shareholders and has set a mid-to long-term dividend payout ratio target of 30%.

This year, due to the uncertainty of COVID-19 impact, annual dividends forecast was 28.0JPY per share, keeping the same amount as the previous year.

Based on the above policy and financial results, the company decided the year-end dividends of 15.0JPY per share and the annual dividends for the year amounts to 29.0JPY per share. The revised dividends for the year-end will be adopted on the condition of approval from shareholders in the general shareholders' meeting to be held on June 22, 2021.

(Reference) Dividend Breakdown

	Dividends per share		
	Interim dividends	Year-end dividends	Annual dividends (total)
FY2021 (ended March 31, 2021)	14.0JPY	15.0JPY	29.0JPY
FY2020 (ended March 31, 2020)	14.0JPY	14.0JPY	28.0JPY

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

###